# Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

> **NCT05920863** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Lenvatinib
- Tislelizumab
- TACE
- Pharmorubicin
- Oxaliplatin

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Tislelizumab, Lenvatinib

## Key facts

- **NCT ID:** NCT05920863
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920863, "Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05920863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*